KIR/HLA combination associated with the risk of complications in celiac disease

International Journal of Biological Markers

Volumn 26, Issue 4, 2011, Pages 221-228

  Caggiari, Laura ^a   Toffoli, Giuseppe ^a   de Re, Valli ^a   Orzes, Nicoletta ^b   Spina, Michele ^a   de Zorzi, Mariangela ^a   Maiero, Stefania ^a   Cannizzaro, Renato ^a   Canzonieri, Vincenzo ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b Ospedale Civile di Gorizia   (Italy)

Author keywords

Autoimmunity; Celiac disease; Enteropathy associated t cell lymphoma; HLA; KIR; MHC; Molecular immunology

Indexed keywords

HLA ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

ADULT; AGED; ARTICLE; CELIAC DISEASE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE; GENOTYPE; GLUTEN FREE DIET; HAPLOTYPE; HLA GENE; HLA SYSTEM; HUMAN; ITALY; KIR GENE; MAJOR CLINICAL STUDY; MALE; NEOPLASM; REFRACTORY CELIAC DISEASE;

ADOLESCENT; ADULT; AGED; CELIAC DISEASE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA ANTIGENS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, KIR; YOUNG ADULT;

EID: 84555203858     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2011.8903     Document Type: Article

References (35)

1. Di Sabatino A, Corazza GR. Coeliac disease. Lancet 2009; 373: 1480-93.
2. Tack GJ, Verbeek WH, Schreurs MW, Mulder CJ. The spectrum of celiac disease: epidemiology, clinical aspects and treatment. Nat Rev Gastroenterol Hepatol 2010; 7: 204-13.
3. De Re V, Simula MP, Notarpietro A, Canzonieri V, Cannizzaro R, Toffoli G. Do gliadin and tissue transglutaminase mediate PPAR downregulation in intestinal cells of patients with coeliac disease? Gut 2010; 59: 1730-1.
4. Biagi F, Lorenzini P, Corazza GR. Literature review on the clinical relationship between ulcerative jejunoileitis, coeliac disease and enteropathy-associated T-cell. Scand J Gastroenterol 2003; 5: 785-90.
5. Catassi C, Bearzi I., Holmes GK. Association of celiac disease and intestinal lymphomas and other cancers. Gastroenterology 2005; 128: S79-S86.
6. Ekstrom SK, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008; 111: 4029-38.
7. Farstad IN, Lundin KE. Gastrointestinal intraepithelial lymphocytes and T cell lymphomas. Gut 2003; 52: 163-4.
8. Green P, Cellier C. Celiac Disease. N Engl J Med 2007; 357: 1731-43.
9. Meresse B, Chen Z, Ciszewski C, et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 2004; 21: 357-66.
10. Di Sabatino A, Ciccocioppo R, Cupelli F, et al. Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease. Gut 2006; 55: 469-77.
11. Simula MP, Cannizzaro R, Canzonieri V, et al. PPAR signaling pathway and cancer-related proteins are involved in celiac disease-associated tissue damage. Mol Med 2010; 16: 199-209.
12. Carrington M, Norman P. The KIR gene cluster. NCBI Bookshelf, 2003.
13. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005; 5: 201-14.
14. Culliford A, Daly J, Diamond B, Rubin M, Green PH. The value of wireless capsule endoscopy in patients with complicated celiac disease. Gastrointest Endosc 2005; 62: 55-61.
15. Oberhuber G, Granditsch G, Vogelsang H. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol 1999; 11: 1185-94.
16. De Re V, Simula MP, Cannizzaro R, et al. Galectin-10, eosinophils, and celiac disease. Ann N Y Acad Sci 2009; 1173: 357-64.
17. Cordovado SK, Hancock LN, Simone AE, Hendrix M, Mueller PW. High-resolution genotyping of HLA-DQA1 in the GoKinD study and identification of novel alleles HLA-DQA1*040102, HLA-DQA1*0402 and HLA-DQA1*0404. Tissue Antigens 2005; 65: 448-58.
18. Martin MP, Nelson G, Lee JH, et al. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 2002; 169: 2818-22.
19. Hiby SE, Walker JJ, O'shaughnessy KM, et al. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med 2004; 200: 957-65.
20. Gomez-Lozano N, Gardiner CM, Parham P, Vilches C. Some human KIR haplotypes contain two KIR2DL5 genes: KIR2DL5A and KIR2DL5B. Immunogenetics 2002; 54: 314-9.
21. Powis SH, Vaughan RW. MHC protocols. In: Methods in molecular biology, Volume 210. Totowa, NJ: Humana Press, 2003; 143-71.
22. Kotsch K, Wehling J, Kohler S, Blasczy KR. Sequencing of HLA class I genes based on the conserved diversity of the noncoding regions sequencing-based typing of the HLA-A gene. Tissue Antigens 1997; 50: 178-91.
23. Du Z, Sharma SK, Spellman S, Reed EF, Rajalingam R. KIR2DL5 alleles mark certain combination of activating KIR genes. Genes Immun 2008; 9: 470-80.
24. Maiuri L, Ciacci C, Ricciardelli I, et al. Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet 2003; 5: 30-7.
25. Harris KM, Fasano A, Mann DL. Monocytes differentiated with IL-15 support Th17 and Th1 responses to wheat gliadin: implications for celiac disease. Clin Immunol 2010; 135: 430-9.
26. Beziat V, Descours B, Parizot C, Debre P, Vieillard V. NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs. PLoS One 2010; 5: e11966.
27. Parsons MS, Zipperlen K, Gallant M, Grant M. Killer cell immunoglobulin-like receptor 3DL1 licenses CD16- mediated effector functions of natural killer cells. J Leukoc Biol 2010; 88: 905-12.
28. Carrington M, Martin MP. The impact of variation at the KIR gene cluster on human disease. Curr Top Microbiol Immunol 2006; 298: 225-57.
29. Khakoo SI, Carrington M. KIR and disease: a model system or system of models? Immunol Rev 2006; 214: 186-201.
30. Rauch A, Laird R, McKinnon E, et al. Influence of inhibitory killer immunoglobulin-like receptors and their HLA-C ligands on resolving hepatitis C virus infection. Tissue Antigens 2007; 69: 237-40.
31. Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 6: 872-4.
32. Qi Y, Martin MP, Gao X, et al. KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathog 2006; 2: 79.
33. Bashirova AA, Martin MP, McVicar DW, Carrington M. The killer immunoglobulinlike receptor gene cluster: tuning the genome for defense. Annu Rev Genomics Hum Genet 2006; 7: 277-300.
34. Alter G, Altfeld M. NK cells in HIV-1 infection: evidence for their role in the control of HIV-1 infection. J Intern Med 2009; 265: 29-42.
35. Kulkarni S, Martin MP, Carrington M. The Yin and Yang of HLA and KIR in human disease. Semin Immunol 2008; 20: 343-52.